Drew Pardoll

Founder at Jounce Therapeutics, Inc.

Drew Pardoll

Drew Pardoll

Founder at Jounce Therapeutics, Inc.

Overview
Career Highlights

Jounce Therapeutics, Inc.
Tizona Therapeutics, Inc.
Amplimmune, Inc.

RelSci Relationships

4302

Number of Boards

26

Relationships
RelSci Relationships are individuals Drew Pardoll likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Tizona Therapeutics, Inc.

Relationship likelihood: Strong

Scientific Co-Founder at Juno Therapeutics, Inc.

Relationship likelihood: Strong

Director, Head & Neck Cancer Research Division at Johns Hopkins University

Relationship likelihood: Strong

Associate Director at Johns Hopkins University - Bloomberg-Kimmel Institute for Cancer Immunotherapy at Sidney Kimmel Comprehensive Cancer Center

Relationship likelihood: Strong

Co-Founder at Tizona Therapeutics, Inc.

Relationship likelihood: Strong

Lloyd J. Old-Virginia & Daniel K. Ludwig Chair in Clinical Investigation, Chief, Melanoma & Immunotherapeutics Service, Director, Parker Institute for Cancer Immunotherapy, Msk & Associate Director, Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Co-Founder at Celsius Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Jounce Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Jounce Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Paths to Drew Pardoll
Potential Connections via
Relationship Science
You
Drew Pardoll
Founder at Jounce Therapeutics, Inc.
Education
Ph.D

The Johns Hopkins University opened in 1876, with the inauguration of its first president, Daniel Coit Gilman. "What are we aiming at?" Gilman asked in his installation address. "The encouragement of research ... and the advancement of individual scholars, who by their excellence will advance the sciences they pursue, and the society where they dwell." The mission laid out by Gilman remains the university's mission today, summed up in a simple but powerful restatement of Gilman's own words: "Knowledge for the world." What Gilman created was a research university, dedicated to advancing both students' knowledge and the state of human knowledge through research and scholarship. Gilman believed that teaching and research are interdependent, that success in one depends on success in the other. A modern university, he believed, must do both well. The realization of Gilman's philosophy at Johns Hopkins, and at other institutions that later attracted Johns Hopkins-trained scholars, revolutionized higher education in America, leading to the research university system as it exists today. After more than 130 years, Johns Hopkins remains a world leader in both teaching and research. Eminent professors mentor top students in the arts and music, the humanities, the social and natural sciences, engineering, international studies, education, business and the health professions. Those same faculty members, and their research colleagues at the university's Applied Physics Laboratory, have each year since 1979 won Johns Hopkins more federal research and development funding than any other university. The university has nine academic divisions and campuses throughout the Baltimore-Washington area. The Krieger School of Arts and Sciences, the Whiting School of Engineering, the School of Education and the Carey Business School are based at the Homewood campus in northern Baltimore. The schools of Medicine, Public Health, and Nursing share a campus in east Baltimore with The Johns Hopkins Hospital. The Peabody Institute, a leading professional school of music, is located on Mount Vernon Place in downtown Baltimore. The Paul H. Nitze School of Advanced International Studies is located in Washington's Dupont Circle area. The Applied Physics Laboratory is a division of the university co-equal to the nine schools, but with a non-academic, research-based mission. APL, located between Baltimore and Washington, supports national security and also pursues space science, exploration of the Solar System and other civilian research and development. Johns Hopkins also has a campus near Rockville in Montgomery County, Md., and has academic facilities in Nanjing, China, and in Bologna, Italy. It maintains a network of continuing education facilities throughout the Baltimore-Washington region, including centers in downtown Baltimore, in downtown Washington and in Columbia. When considered in partnership with its sister institution, the Johns Hopkins Hospital and Health System, the university is Maryland's largest employer and contributes more than $10 billion a year to the state's economy

Career History
Founder
2013 - Current

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Member, Editorial Board
Prior
Scientific Founder
Prior

Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD.

Boards & Committees
Member, Scientific Advisory Board
2017 - Current

Immunomic Therapeutics, Inc. engages in the discovery and development of drugs. The firm specializes in DNA vaccines, lamp technology, allergy, oncology, animal health and infectious diseases. The company was founded by William G. Hearl and Thomas J. August in 2005 and is headquartered in Hershey, PA.

Member, Scientific Advisory Board
2017 - Current

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Member, Scientific Advisory Board
2014 - Current

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Member, Scientific Advisory Council
Current

THE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BY FUELING THE DISCOVERY AND DEVLEOPMENT OF POWERFUL IMMUNOTHERAPIES FOR ALL TYPES OF CANCER.

Member, Grant Review Committee
Current

The Melanoma Research Alliance (MRA) is the largest non-profit funder of melanoma research. Since its founding in 2007, MRA has committed $100 million in funding to advance our understanding of this disease. MRA funds projects in the areas of prevention, diagnosis, and treatment, with the majority of funding allocated for melanoma treatment.

Director
Current

The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$1,000 - $4,999
2012

THE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BY FUELING THE DISCOVERY AND DEVLEOPMENT OF POWERFUL IMMUNOTHERAPIES FOR ALL TYPES OF CANCER.

Investments
Details Hidden

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew Pardoll, Dario Vignali, and Jedd Wolchok and is headquartered in South San Francisco, CA.

Details Hidden

Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA.

Details Hidden

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Drew Pardoll. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Drew Pardoll's profile does not indicate a business or promotional relationship of any kind between RelSci and Drew Pardoll.